Ortho Clinical Diagnostics announced U.S. FDA approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROSĀ® 5600 Integrated and VITROSĀ® 3600 Immunodiagnostic Systems.Ā This is the first HIV diagnostic assay approved for an integrated system in the United States, allowing laboratories to run HIV and other routine tests on a single testing platform and eliminating the need for expensive batch testing of multiple patient samples.
Mike Samoszuk, M.D., Chief Medical Officer, Ortho Clinical Diagnostics said, By providing a fast, cost-effective and reliable method for testing HIV, the VITROSĀ® Anti-HIV 1+2 Assay will help enhance the clinical laboratoryās ability to adhere to the Centers for Disease Control and Prevention (CDC) HIV screening guidelines, while at the same time increasing the labās productivity and efficiency. This approval underscores Ortho Clinical Diagnosticsā continuing commitment to providing clinical laboratories with tests that help detect diseases earlier for better patient outcomes.
The CDC recommends routine screening for people between the ages of 13 and 64 during annual check-ups, pregnant women either before or during pregnancy, and newborns.Ā Currently, more than 230,000 people living with HIV in the U.S. are unaware they have the disease, increasing the need for routine screening.1Ā HIV screening plays an invaluable role in early disease detection, prevention and treatment.
